ThrombosisNCT07358416
Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
An observational study of Thrombosis and Bleeding, run by Petrovsky National Research Centre of Surgery at 1 site in Russia.
Trial summary
The goal of this retrospective clinical trial is to find out association antiplatelet and anticoagulant therapy with perioperative complications in non-cardiac vascular surgery in patients . Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure
- What is being tested?
- Aspirin, Clopidogrel and Ticagrelor
- How many people
- 500 participants
- Where
- 1 siteRussia
- Study dates
- 1 May 2025to 28 Feb 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with surgical treatment of atherosclerotic lesions of the main arteries.
Who may be able to join
- Patients who received surgical treatment on the main arteries.
Who cannot join
- Patients who received surgical treatment on the main veins.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Determination the Safety of Disaggregant and Anticoagulant Therapy in the Development of Complications in Noncardiac Vascular Surgery.
The goal of this retrospective clinical trial is to find out association antiplatelet and anticoagulant therapy with perioperative complications in non-cardiac vascular surgery in patients . The main questions it aims to answer are:
Does the use of antiplatelet agents and anticoagulants affect the development of complications in the perioperative period during operations on the main arteries? Does discontinuing antiplatelet and anticoagulant medications affect the development of perioperative complications in major artery surgeries?? Researchers will compare with patients who didn't use antiplatelets and anticoagulant drugs to see ift he incidence of complications comparable?
This is a retrospective study based on the analysis of medical records (case histories).
- Being tested
- Aspirin, Clopidogrel, Ticagrelor, Dabigatran, Rivaroxaban
- Keywords
- Vascular surgery, Antiplatelet, Anticoagulants, complication, trombosis, bleeding
- Medical subject headings
- Thrombosis, Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AspirinDrug
Patients who take aspirin until the operation day
ClopidogrelDrug
Patients who take clopidogrel until the operation day
TicagrelorDrug
Patients who take ticagrelor until the operation day
DabigatranDrug
Patients who take dabigatran until the operation day
RivaroxabanDrug
Patients who take rivaroxaban until the operation day
ApixabanDrug
Patients who take apixaban until the operation day
WarfarinDrug
Patients who take warfarin until the operation day
aspirin + clopidogrelDrug
Patients who take aspirin and clopidogrel until the operation day
Aspirin + TicagrelorDrug
Patients who take aspirin and ticagrelor until the operation day
Aspirin + ApixabanDrug
Patients who take aspirin and apixaban until the operation day
Aspirin + rivaroxabanDrug
Patients who take aspirin and rivaroxaban until the operation day
Clopidogrel + ApixabanDrug
Patients who take clopidogrel and apixaban until the operation day
Clopidogrel + RivaroxabanDrug
Patients who take clopidogrel and rivaroxaban until the operation day
| Study group | Role | What they receive |
|---|---|---|
| Control | Patients who did not take antiplatelet agents and anticoagulants | |
| Antiplatelet and anticoagulants | Patients who use antiplatelet agents and anticoagulants until the operation day Receives: Drug: Aspirin; Drug: Clopidogrel; Drug: Ticagrelor; Drug: Dabigatran; Drug: Rivaroxaban; Drug: Apixaban; Drug: Warfarin; Drug: aspirin + clopidogrel; Drug: Aspirin + Ticagrelor; Drug: Aspirin + Apixaban; Drug: Aspirin + rivaroxaban; Drug: Clopidogrel + Apixaban; Drug: Clopidogrel + Rivaroxaban | |
| Discontinuation of antiplatelet and anticoagulants | Patients who discontinuate antiplatelet agents and anticoagulants until the operation day |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bleeding
Case of bleeding or haematoma development
Measured: First 24 hours after operation
Secondary outcomes (1)
Trombosis
Measured: First 24 hours after operation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2026
- Study start1 May 2025
- Primary completion12 Feb 2026 (estimated)
- Study completion28 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ThrombosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Petrovsky National Research Centre of Surgery
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07358416
- Sponsor's protocol ID
- ComplVasc2025Retro
- Status last verified
- Jan 2026
- First submitted
- 14 Jan 2026
- Last updated
- 22 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 22 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Determination the Safety of Disaggregant and Anticoagulant Therapy in the Development of Complications in Noncardiac Vascular Surgery.
- ClinicalTrials.gov ID
- NCT07358416
- Acronym / sponsor ID
- ComplVasc2025Retro
- Keywords
- Vascular surgery, Antiplatelet, Anticoagulants, complication, trombosis, bleeding
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Petrovsky National Research Centre of SurgeryUniversity, hospital or other
- Study start
- 1 May 2025 (actual)
- Primary completion
- 12 Feb 2026 (estimated)
- Study completion
- 28 Feb 2026 (estimated)
- First posted
- 22 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this retrospective clinical trial is to find out association antiplatelet and anticoagulant therapy with perioperative complications in non-cardiac vascular surgery in patients . The main questions it aims to answer are:
Does the use of antiplatelet agents and anticoagulants affect the development of complications in the perioperative period during operations on the main arteries? Does discontinuing antiplatelet and anticoagulant medications affect the development of perioperative complications in major artery surgeries?? Researchers will compare with patients who didn't use antiplatelets and anticoagulant drugs to see ift he incidence of complications comparable?
This is a retrospective study based on the analysis of medical records (case histories).
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control | – | –Patients who did not take antiplatelet agents and anticoagulants |
| Antiplatelet and anticoagulants | – | Drug: Aspirin, Drug: Clopidogrel, Drug: Ticagrelor, Drug: Dabigatran, Drug: Rivaroxaban, Drug: Apixaban, Drug: Warfarin, Drug: aspirin + clopidogrel, Drug: Aspirin + Ticagrelor, Drug: Aspirin + Apixaban, Drug: Aspirin + rivaroxaban, Drug: Clopidogrel + Apixaban, Drug: Clopidogrel + RivaroxabanPatients who use antiplatelet agents and anticoagulants until the operation day |
| Discontinuation of antiplatelet and anticoagulants | – | –Patients who discontinuate antiplatelet agents and anticoagulants until the operation day |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with surgical treatment of atherosclerotic lesions of the main arteries.
Key inclusion criteria (1 listed)
- Patients who received surgical treatment on the main arteries.
Key exclusion criteria (1 listed)
- Patients who received surgical treatment on the main veins.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AspirinPatients who take aspirin until the operation day | Drug | Antiplatelet and anticoagulants |
| ClopidogrelPatients who take clopidogrel until the operation day | Drug | Antiplatelet and anticoagulants |
| TicagrelorPatients who take ticagrelor until the operation day | Drug | Antiplatelet and anticoagulants |
| DabigatranPatients who take dabigatran until the operation day | Drug | Antiplatelet and anticoagulants |
| RivaroxabanPatients who take rivaroxaban until the operation day | Drug | Antiplatelet and anticoagulants |
| ApixabanPatients who take apixaban until the operation day | Drug | Antiplatelet and anticoagulants |
| WarfarinPatients who take warfarin until the operation day | Drug | Antiplatelet and anticoagulants |
| aspirin + clopidogrelPatients who take aspirin and clopidogrel until the operation day | Drug | Antiplatelet and anticoagulants |
| Aspirin + TicagrelorPatients who take aspirin and ticagrelor until the operation day | Drug | Antiplatelet and anticoagulants |
| Aspirin + ApixabanPatients who take aspirin and apixaban until the operation day | Drug | Antiplatelet and anticoagulants |
| Aspirin + rivaroxabanPatients who take aspirin and rivaroxaban until the operation day | Drug | Antiplatelet and anticoagulants |
| Clopidogrel + ApixabanPatients who take clopidogrel and apixaban until the operation day | Drug | Antiplatelet and anticoagulants |
| Clopidogrel + RivaroxabanPatients who take clopidogrel and rivaroxaban until the operation day | Drug | Antiplatelet and anticoagulants |
Primary outcome
Bleeding
Time frame: First 24 hours after operation
Case of bleeding or haematoma development
1 secondary outcome
Trombosis
Time frame: First 24 hours after operation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2026.
- Individual participant dataSharing planned: Yes
Related trials for Thrombosis
Not yet recruitingPhase 3
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
RecruitingObservational study
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
Pulmonary Embolism
RecruitingPhase 2
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
HCC
Not yet recruiting
Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism
Pulmonary Embolism (PE), Pulmonary Embolism With Right Ventricle Enlargement
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thrombosis and Bleeding, run by Petrovsky National Research Centre of Surgery at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 22 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bleeding (time frame: First 24 hours after operation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2026.